Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos, Exelixis Pen Gene Function Partnership

NEW YORK, Jan. 23 - Galapagos Genomics and Exelixis have penned an agreement under which Exelixis will use Galapagos' adenoviral technology to analyze gene function in cell-based assays.

 

Galapagos, a functional genomics company based in Belgium, will reconstruct recombinant adenoviruses that include genes selected by Exelixis. Researchers at Exelixis will then introduce the vectors into a range of cell types in order to evaluate protein function of the selected genes in disease-relevant pathways.

 

Financial details of the deal were not disclosed.

 

Galapagos' technology can be used to link genes with a range of phenotypic characteristics like morphology, motility, proliferation, differentiation and signal transduction.

The Scan

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.

EHR Quality Improvement Study Detects Demographic-Related Deficiencies in Cancer Family History Data

In a retrospective analysis in JAMA Network Open, researchers find that sex, ethnicity, language, and other features coincide with the quality of cancer family history information in a patient's record.

Inflammatory Bowel Disease Linked to Gut Microbiome Community Structure Gradient in Meta-Analysis

Bringing together data from prior studies, researchers in Genome Biology track down microbial taxa and a population structure gradient with ties to ulcerative colitis or Crohn's disease.

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.